Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ivax/Serono Oral MS Therapy Mylinax Efficacy Trials Planned For 2004

This article was originally published in The Pink Sheet Daily

Executive Summary

Exact nature of the trials will be determined following discussion with FDA, Ivax says. Trial design could be a challenge in light of the troubled regulatory history of injectable cladribine for MS, previously pursued by J&J.

You may also be interested in...

Rebif Gains New Multiple Sclerosis Rx Share Following Tysabri Withdrawal

Rebif is the leader in new prescription growth with a 22.4% share, an all-time high, at the end of March, Serono says. The company is focusing marketing of Rebif on efficacy, a message to which Tysabri helped draw attention. Serono expects Rebif to emerge as the global MS leader by 2006.

Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal

Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts